Diabetes

As physicians, we must be aptly prepared to address risk factors facing our diabetic patients. Trial results reveal intensive diabetes treatment aimed at normalizing long-term glucose control decreases risks, such as nonfatal myocardial infarctions, nonfatal strokes and fatal cardiovascular events. A diet comprised of low-GI starchy foods showed lowered glucose and insulin responses throughout the day—and improvement in the lipid profile and capacity for fibrinolysis, suggesting a therapeutic potential. Review current research and medical articles on diabetes to stay informed.


Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update.pdf

This 2007 update provides the most current clinical recommendations for the prevention of CVD in women 20 years of age and is based on a systematic search of the highest-quality science, interpreted by experts in the fields of cardiology, epidemiology, family medicine, gynecology, internal medicine, neurology, nursing, public health, statistics, and surgery. These guidelines cover the primary and secondary prevention of chronic atherosclerotic vascular diseases. More acute management of vascular disease in the periprocedural or immediate posthospital settings and of valvular heart disease is covered in other AHA guidelines. Management of heart failure, atrial fibrillation for stroke prevention, and CVD risk factors during pregnancy is beyond the scope of the present document.
Mosca, L., Banka, C.L., Benjamin, E.J., Berra, K., Bushnell, C., Dolor, R.J., et al. (2007). Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update [Electronic version]. Circulation, 115(11), 1481-1501. Retrieved May 2, 2007.

An Alarming Link.  New Studies Say Diabetes Leads to Alzheimer’s. Still, That Raises Hope for Novel Brain Treatments.pdf

At a major Alzheimer's Association meeting in Madrid, researchers behind the Veterans Administration Puget Sound Health Care System experiment in Seattle and other experts are making a strong case that diabetes hammers not just the body but the mind. Indeed, it may be a precursor to Alzheimer's. As blood sugar control gets worse in diabetics, Alzheimer's risk climbs astronomically, one study found.
Fischman, J. (2006, July 24). An alarming link.  New studies say diabetes leads to Alzheimer’s. Still, that raises hope for novel brain treatments [Electronic version]. U.S. News & World Report Website. Retrieved August 17, 2006.

The Age Related Decrease in Testosterone is Significantly Exacerbated in Obese Men with the Metabolic Syndrome. What are the Implications for the Relatively High Incidence of Erectile Dysfunction Observed in These Men?.pdf

This study demonstrated that aging men with obesity and the metabolic syndrome have a significant decrease in total serum testosterone levels compared to aging, metabolically healthy men. These data suggest that the well established association between erectile dysfunction and pre-diabetes/diabetes (particularly in obese pre-diabetic/diabetic patients) may involve a hormonal component.
Kaplan, S.A., Meehan, A.G. & Shah, A. (2006). The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men? [Electronic version]. The Journal of Urology, 176(4 Pt. 1), 1524-1527, discussion 1527-1528. Retrieved November 27, 2006.

Lowering Dietary Glycemic Load for Weight Control and Cardiovascular Health: A Matter of Quality.pdf

This study concludes that although significant differences in neurohormonal responses to different types of carbohydrates have long been recognized, until recently this knowledge has not been comprehensively and systematically applied to the study of diet and CVD in populations or to the development of food-composition tables in guiding dietary practice.
Liu. S. (2006). Lowering dietary glycemic load for weight control and cardiovascular health: a matter of quality [Electronic version]. Archives of Internal Medicine, 166(14), 1438-1439. Retrieved November 14, 2006.

Prevalence of Hypogonadism in Males Aged at Least 45 Years: The HIM study.pdf

According to this study, based on TT concentration, the prevalence of hypogonadism in men reporting to primary care offices was estimated to be 38.7%. The medical conditions that occurred significantly more frequently among hypogonadal men than eugonadal men included increased BMI, hypertension, hyperlipidaemia, diabetes, and asthma or COPD. As men age, they are susceptible to conditions that share many of the same symptoms similar to hypogonadism. The presence of these conditions may, in effect, mask underlying hypogonadism and negatively impact quality of life.
Mulligan, T., Frick, M.F., Zuraw, Q.C., Stemhagen, A. & McWhirter, C. (2006). Prevalence of hypogonadism in males aged at least 45 years: the HIM study [Electronic version]. International Journal of Clinical Practice, 60(7), 762-769. Retrieved November 27, 2006.

Low Serum Testosterone and Mortality in Male Veterans.pdf

This study used a clinical database to identify men older than 40 years with repeated testosterone levels obtained from October 1, 1994 to December 31, 1999, and without diagnosed prostate cancer.  It concluded that low testosterone levels were associated with increased mortality in male veterans. Further prospective studies are needed to examine the association between low testosterone levels and mortality.
Shores, M.M., Matsumoto, A.M., Sloan, K.L. & Kivlahan, D.R. (2006). Low serum testosterone and mortality in male veterans [Electronic version]. Archives of Internal Medicine, 166(15), 1660-1665. Retrieved August 28, 2006.

GE Healthcare Announces Most Extensive Body Composition Reference Database in China.pdf

GE Healthcare, a unit of General Electric Company (NYSE: GE), announced that the company has developed the most extensive body composition reference database to evaluate total body composition in Chinese women. The reference database provides improved confidence for Chinese physicians in evaluating clinical conditions such as obesity, eating disorders, diseases that cause muscle wasting, and conditions that may increase the risk of diabetes and heart disease. The new reference database was presented at the 27th Annual Meeting of the American Society for Bone and Mineral Research meeting in Nashville, TN September 23-27.
(2005, September 23). GE Healthcare announces most extensive body composition reference database in China [Electronic version]. (PDF)

Scientists Believe Type 3 Diabetes Uncovered.pdf

After discovering that insulin and its related proteins are produced in the brain and that reduced levels of both contribute to Alzheimer’s, scientists believe they may have found a new type of Diabetes.
Scientists believe type 3 diabetes uncovered. (2005) [Electronic version]. Nutraingredientsusa.com. Retrieved May 17, 2005.

Review of Insulin and Insulin-Like Growth Factor Expression, Signaling, and Malfunction in the Central Nervous System: Relevance to Alzheimer's Disease.pdf

This review details what is currently known about insulin, insulin-like growth factor type I (IGF-I) and IGF-II proteins and their corresponding receptors in the brain, and delineates the major controversies pertaining to alterations in the expression and function of these molecules in AD.
de la Monte, S.M. & Wands, J.R. (2005). Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: Relevance to Alzheimer's disease [Electronic version]. Journal of Alzheimer’s Disease, 7(1), 45-61. Retrieved August 17, 2006.

Type 1 and Type 2 Diabetes: Are They the Same Disorder? The Accelerator Hypothesis Offers an Alternative to the Current Theories.pdf

According to this article, for more than 30 years, type 1 and type 2 diabetes have been viewed as different disorders. Type 1 has been cast as an autoimmune disease, and the association of type 1 diabetes with HLA genotype has been thoroughly studied. New research has suggested that a shift in the diabetes paradigm may be coming. The “accelerator hypothesis” is a relatively new interpretation of diabetes.
Levitan, D. (2005). Type 1 and type 2 diabetes: Are they the same disorder? The accelerator hypothesis offers and alternative to the current theories [Electronic version]. Endocrine Today, 3(8), 13. Retrieved October 11, 2005.

Abdominal Obesity a Better Marker of Insulin Resistance Syndrome. Insulin Resistance Syndrome Increases Risk for Metabolic Syndrome, Type 2 Diabetes, CVD and PCOS.pdf

According to Mary Ann Banerji, MD, associate professor of medicine and endocrinology at SUNY Downstate Medical Center in Brooklyn, N.Y., abdominal obesity may be a better marker of insulin resistance syndrome than other indicators such as BMI and weight.  Banerji spoke about obesity and its association with insulin resistance syndrome at the 65th Scientific Sessions of the American Diabetes Association.
Lewis, J. (2005). Abdominal obesity a better marker of insulin resistance syndrome. Insulin resistance syndrome increases risk for metabolic syndrome, type 2 diabetes, CVD and PCOS [Electronic version]. Endocrine Today, 3(8), 14.  (PDF)

Improved Glucose Control Reduced Long-Term Cardiovascular Complications. DCCT: Intensive Glycemic Control Reduced Risk of MI and Stroke in Patients with Type 1 Diabetes.pdf

This article discusses how intensive therapy should begin as early as possible to reduce the risk of long-term complications of type 1 diabetes, according to the latest results from the Diabetes Control and Complications Trial. The new Diabetes Control and Complications Trial (DCCT) results demonstrated that intensive diabetes treatment aimed at normalizing long-term glucose control decreased the risk of nonfatal myocardial infarctions, nonfatal strokes and fatal cardiovascular events.
Lewis, J. (2005). Improved glucose control reduced long-term cardiovascular complications. DCCT: Intensive glycemic control reduced risk of MI and stroke in patients with type 1 diabetes [Electronic version]. Endocrine Today, 3(8), 4. Retrieved October 11, 2005.

Diabetes Management Remains Suboptimal: Even Academic Centers Neglect Curbing Risk Ractors.pdf

The potential complications associated with the treatment of Diabetes require aggressive management by medical professionals.  This article discusses concerns about the need for doctors to do a better job of addressing their Diabetic patients’ risk factors.
Mitka, M. (2005). Diabetes management remains suboptimal: even academic centers neglect curbing risk factors [Electronic version]. The Journal of the American Medical Association, 293(15), 1845-1846. Retrieved May 17, 2005.

Midlife Cardiovascular Risk Factors and Risk of Dementia in Late Life.pdf

The aim of this study was to evaluate if midlife cardiovascular risk factors are associated with risk of late-life dementia in a large, diverse cohort.  It concluded that the presence of multiple cardiovascular risk factors at midlife substantially increases risk of late-life dementia in a dose dependent manner.
Whitmer, R.A., Sidney, S., Selby, J., Johnston, S.C. & Yaffe, K. (2005). Midlife cardiovascular risk factors and risk of dementia in late life [Electronic version]. Neurology, 64(2), 277-281. Retrieved August 17, 2006.

Insulin-Like Growth Factor-1 as a Vascular Protective Factor.pdf

According to this study, until recently, IGF-1 was considered a mediator of vascular disease. Increasing evidence indicates, instead, that IGF-1 protects against endothelial dysfunction, atherosclerotic plaque development, the metabolic syndrome, clinical instability, and ischemic myocardial damage.
Conti, E., Carrozza, C., Capoluongo, E., Volpe, M., Crea, F., Zuppi, C., et al. (2004). Insulin-like growth factor-1 as a vascular protective factor [Electronic version]. Circulation, 110(15), 2260-2265. Retrieved May 18, 2005.

Low Testosterone Common in Type 2 Diabetes Study: 1 in 3 Diabetic Men May Suffer Low Sex Hormone Levels.pdf

A third of men with type 2 diabetes have low testosterone levels, a new study suggests. Testosterone helps men reduce body fat and improves the way their bodies handle insulin. So low testosterone levels may have serious consequences for men with diabetes, suggests Sandeep Dhindsa, MD, of State University of New York at Buffalo.
DeNoon, D. (2004, December 1). Low testosterone common in type 2 diabetes
study: 1 in 3 diabetic men may suffer low sex hormone levels. WebMD Health. Retrieved December 12, 2006.

Frequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes.pdf

Type 2 diabetes is associated with lower total testosterone levels in cross-sectional studies. However, it is not known whether the defect is primary or secondary.  This article concludes that hypogonadotropic hypogonadism occurs commonly in type 2 diabetes.
Dhindsa, S., Prabhakar, S., Sethi, M., Bandyopadhyay, A., Chaudhuri, A. & Dandona, P. (2004). Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes [Electronic version].  Journal of Clinical Endocrinology and Metabolism, 89(11), 5462-5468. Retrieved January 19, 2005.

Review of the Book The Sexy Years: Discover the Hormone Connection: The Secret to Fabulous Sex, Great Health, and Vitality, for Women and Men.pdf

Review by Amazon.com of Suzanne Somers’ book The Sexy Years: Discover the Hormone Connection: The Secret to Fabulous Sex, Great Health, and Vitality, for Women and Men.
Lightner, J. (2004). [Review of the book The sexy years: Discover the hormone connection: the secret to fabulous sex, great health, and vitality, for women and men]. Retrieved September 10, 2004.

Low Androgenization Index in Elderly Women and Elderly Men with Alzheimer's Disease.pdf

The authors of this study investigated whether testosterone levels and testosterone availability differ between older lean subjects with and without Alzheimer's disease (AD). Sex hormone binding globulin (SHBG) and estradiol levels were higher, whereas the free androgenization index (FAI) was lower, in lean subjects with AD than in lean subjects without AD. Factors involved in the increase of SHBG secretion could have an important role in the lower testosterone availability of subjects with AD.
Paoletti, A.M., Congia, S., Lello, S., Tedde, D., Orru, M., et al. (2004). Low androgenization index in elderly women and elderly men with Alzheimer's disease [Electronic version]. Neurology. 62(2), 301-303. Retrieved September 27, 2005.

Diet Composition and the Risk of Type 2 Diabetes: Epidemiological and Clinical Evidence.pdf

This article concludes that new emphasis on prevention by multiple lifestyle modifications, including moderate changes in the composition of the habitual diet, might limit the dramatic increase in incidence of type 2 diabetes envisaged worldwide.
Parillo, M. & Riccardi, G. (2004). Diet composition and the risk of type 2 diabetes: epidemiological and clinical evidence [Electronic version]. The British Journal of Nutrition, 92(1), 7-19. Retrieved September 27, 2005.

The Paradox of the Insulin/IGF-1 Signaling Pathway in Longevity.pdf

This review focuses on the downstream cascade of events in the insulin and IGF-1 signaling to identify specific pathways that are relevant to human longevity.
Rincon, M., Muzumdar, R., Atzmon, G. & Barzilai, N. (2004). The paradox of the insulin/IGF-1 signaling pathway in longevity [Electronic version].  Mechanisms of Ageing & Development, 125(6), 397-403. Retrieved September 19, 2005.

Diabetes Mellitus and Risk of Dementia in the Kungsholmen Project: A 6-Year Follow-up Study.pdf

The authors of this study investigated the relationship between diabetes mellitus and risk of dementia, Alzheimer disease (AD), and vascular dementia (VaD). They concluded that diabetes mellitus increases the risk of dementia, and VaD in particular, in very old people. The risk for dementia and VaD is especially high when diabetes mellitus occurs together with severe systolic hypertension or heart disease.
Xu, W.L., Qiu, C.X., Wahlin, A., Winblad, B. & Fratiglioni, L. (2004). Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study [Electronic version]. Neurology, 63(7), 1181-1186. Retrieved August 17, 2006.

Relationship of Walking to Mortality Among US Adults with Diabetes.pdf

This study concluded that walking was associated with lower mortality across a diverse spectrum of adults with diabetes. One death per year may be preventable for every 61 people who could be persuaded to walk at least 2 h/wk.
Gregg, E.W., Gerzoff, R.B., Caspersen, C.J., Williamson, D.F. & Narayan, K.M. (2003). Relationship of walking to mortality among US adults with diabetes [Electronic version]. Archives of Internal Medicine, 163(12), 1440-1447. Retrieved September 27, 2005.

Insulin Resistance and Prostate Cancer Risk.pdf

In this study, the associations between prostate cancer risk and insulin sensitivity or resistance were independent of total caloric intake and serum levels of insulin-like growth factors, sex hormones, and sex hormone-binding globulin. Because of the retrospective design of this study, the role of insulin resistance in prostate cancer needs to be confirmed in prospective studies.
Hsing, A.W., Gao, Y.T., Chua, S., Jr., Deng, J. & Stanczyk, F.Z. (2003). Insulin resistance and prostate cancer risk [Electronic version]. Journal of the National Cancer Institute, 95(1), 67-71. Retrieved September 27, 2005.

A Diet Rich in Coconut Oil Reduces Diurnal Postprandial Variations in Circulating Tissue Plasminogen Activator Antigen and Fasting Lipoprotein (a) Compared with a Diet Rich in Unsaturated Fat in Women.pdf

The results of this study indicated that a coconut oil-based diet (HSAFA-diet) lowers postprandial t-PA antigen concentration, and this may favorably affect the fibrinolytic system and the Lp(a) concentration compared with the HUFA-diet. The proportions of dietary saturated fatty acids more than the percentage of saturated fat energy seem to have a beneficial influence on Lp(a) levels.
Muller, H., Lindman, A.S., Blomfeldt, A., Seljeflot, I. & Pedersen, J.I. (2003). A diet rich in coconut oil reduces diurnal postprandial variations in circulating tissue plasminogen activator antigen and fasting lipoprotein (a) compared with a diet rich in unsaturated fat in women [Electronic version]. The Journal of Nutrition, 133(11), 3422-3427. Retrieved November 1, 2005.

Lifetime Risk for Diabetes Mellitus in the United States.pdf

This study concluded that for individuals born in the United States in 2000, the lifetime probability of being diagnosed with diabetes mellitus is substantial. Primary prevention of diabetes and its complications are important public health priorities.
Narayan, K.M., Boyle, J.P., Thompson, T.J., Sorensen, S.W. & Williamson, D.F. (2003). Lifetime Risk for Diabetes Mellitus in the United States [Electronic version]. The Journal of the American Medical Association, 290(14), 1884-1890. Retrieved September 27, 2005.

Overweight, Obesity, and Cancer Risk.pdf

According to this article, in addition to an increase in the risk of cardiovascular disease and type II diabetes, the evidence summarized here shows that excess body weight is directly associated with risk of cancer at several organ sites, including colon, breast (in postmenopausal women), endometrium, oesophagus, and kidney.
Bianchini, F., Kaaks, R. & Vainio, H. (2002). Overweight, obesity, and cancer risk [Electronic version]. The Lancet Oncology, 3(9), 565-574. Retrieved January 4, 2006.

Severely Burned Patients After Surgery: Recombinant Human Growth Hormone Therapy its Metabolic Effects.pdf

This study concludes that recombinant human growth hormone (rhGH) has a beneficial effect on metabolism in patients who are severely burned.  Hyperglycemia, however, is apt to occur and water, Na(+), Cl(-) retention are suggested.  Fifty patients were studied.
Chai, J., Hao, D., Wu, Y., Shen, C., Guo, Z. & Sheng, Z. (2002). [Severely burned patients after surgery: recombinant human growth hormone therapy its metabolic effects] [Article in Chinese] [Electronic version]. Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery], 40(2), 107-111. Retrieved May 18, 2005.

The Influence of Recombinant Human Growth Hormones on the Systemic Metabolism After Severe Burn.pdf

The conclusion of this study involving twenty-four burn patients was that a small dose of recombinant human growth hormone could promote systemic protein synthesis with no side effects on blood glucose levels.
Chen, Z., Gu, C., Wang, Z., Ye, X., Wang, X., Li, H., Shen, Y. & Li, J. (2002). [The influence of recombinant human growth hormones on the systemic metabolism after severe burn] [Article in Chinese] [Electronic version]. Zhonghua Shao Shang Za Zhi [Chinese Journal of Burns], 18(3), 183-185. Retrieved May 18, 2005.

Hormone Replacement Therapy, Insulin Sensitivity, and Abdominal Obesity in Postmenopausal Women.pdf

The authors concluded that postmenopausal women taking oral estrogen or those taking a combination of estrogen and HRT are more insulin-resistant than women not on HRT, even when women are of comparable total and abdominal adiposity.
Ryan, A.S., Nicklas, B.J. & Berman, D.M. (2002). Hormone replacement therapy, insulin sensitivity, and abdominal obesity in postmenopausal women [Electronic version]. Diabetes Care, 25(1), 127-133. Retrieved January 19, 2006.

Low-Dose Growth Hormone Treatment Combined with Diet Restriction Decreases Insulin Resistance by Reducing Visceral Fat and Increasing Muscle Mass in Obese Type 2 Diabetic Patients.pdf

This study concluded that low-dose GH treatment combined with dietary restriction resulted not only in a decrease of visceral fat but also in an increase of muscle mass with a consequent improvement of the insulin resistance observed in obese type 2 diabetic patients.

Nam, S.Y., Kim, K.R., Cha, B.S., Song, Y.D., Lim, S.K., Lee, H.C., et al. (2001). Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients [Electronic version].  International Journal of Obesity and Related Metabolic Disorders, 25(8), 1101-1107. Retrieved January 19, 2006.

The Effect of 30 Months of Low-Dose Replacement Therapy with Recombinant Human Growth Hormone (rhGH) on Insulin and C-Peptide Kinetics, Insulin Secretion, Insulin Sensitivity, Glucose Effectiveness, and Body Composition in GH-Deficient Adults.pdf

This study concludes that long-term rhGH-replacement therapy in GH deficiency adults induced a significant deterioration in glucose tolerance, profound changes in kinetics of C-peptide, and insulin and prehepatic insulin secretion, despite an increase in lean body mass and a reduction of fat mass. Therefore, rhGH treatment may precipitate diabetes in some patients already susceptible to the disorder.
Rosenfalck, A.M., Maghsoudi, S., Fisker, S., Jorgensen, J.O., Christiansen, J.S., Hilsted, J., et al. (2000). The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults [Electronic version]. The Journal of Clinical Endocrinology and Metabolism, 85(11), 4173-4181. Retrieved July 21, 2003.

Consequences of the Diabetic Status on the Oxidant/Antioxidant Balance.pdf

The aim of this paper was to review the consequences of the diabetic status on the oxidant/antioxidant balance.
Bonnefont-Rousselot, D., Bastard, J.P., Jaudon, M.C. & Delattre, J. (2000). Consequences of the diabetic status on the oxidant/antioxidant balance [Electronic version]. Diabetes & Metabolism, 26(3), 163-176. Retrieved September 27, 2005.

Individualized Low-Dose Growth Hormone (GH) Treatment in GH-Deficient Adults with Childhood-Onset Disease: Metabolic Effects During Fasting and Hypoglycemia.pdf

In this study, GH therapy resulted in increased insulin resistance during hypoglycemia, without changes in the counterregulatory hormonal responses, serum IGFBP-1, or serum FFA.
Bulow, B., Agardh, C.D., Eckert, B. & Erfurth, E.M. (1999). Individualized low-dose growth hormone (GH) treatment in GH-deficient adults with childhood-onset disease: metabolic effects during fasting and hypoglycemia [Electronic version]. Metabolism: Clinical and Experimental, 48(8), 1003-1010. Retrieved September 14, 2005.

Improved Glycemic Control and Lipid Profile and Normalized Fibrinolytic Activity on a Low-Glycemic Index Diet in Type 2 Diabetic Patients.pdf

This study concludes that a diet characterized by low-GI starchy foods lowers the glucose and insulin responses throughout the day and improves the lipid profile and capacity for fibrinolysis, suggesting a therapeutic potential in diabetes.
Jarvi, A.E., Karlstrom, B.E., Granfeldt, Y.E., Bjorck, I.E., Asp, N.G., et al. (1999). Improved glycemic control and lipid profile and normalized fibrinolytic activity on a low-glycemic index diet in type 2 diabetic patients [Electronic version]. Diabetes Care, 22(1), 10-18. Retrieved September 14, 2005.

Long-Term Effects of Growth Hormone Therapy on Intermediary Metabolism and Insulin Sensitivity in Hypopituitary Adults.pdf

This study found that the available evidence suggests that concerns regarding glucose intolerance in patients receiving long-term GH therapy have not been substantiated. The beneficial effects on body composition, and on total and low density lipoprotein cholesterol levels, persisted over the 4 years of study.
Johnston, D.G., Al-Shoumer, K.A., Chrisoulidou, A., Kousta, E., Beshyah, S. & Robinson, S. (1999). Long-term effects of growth hormone therapy on intermediary metabolism and insulin sensitivity in hypopituitary adults [Electronic version]. Journal of Endocrinological Investigation, 22(5 Suppl.), 37-40. Retrieved January 25, 2006.

The Effect of Hormonal Replacement Therapy on the Vascular Reactivity and Endothelial Function of Healthy Individuals and Individuals with Type 2 Diabetes.pdf

This study concludes that menopausal status and type 2 diabetes are associated with impaired microvascular reactivity. HRT substantially improves microvascular reactivity in postmenopausal healthy women. In contrast, the effect of HRT on the microvascular reactivity of postmenopausal diabetic women is less apparent. However, the use of HRT among women with diabetes is associated with lower sICAM levels, suggesting an attenuation in endothelial activation.
Lim, S.C., Caballero, A.E., Arora, S., Smakowski, P., Bashoff, E.M., Brown, F.M., et al. (1999). The effect of hormonal replacement therapy on the vascular reactivity and endothelial function of healthy individuals and individuals with type 2 diabetes [Electronic version]. The Journal of Clinical Endocrinology and Metabolism, 84(11), 4159-4164. Retrieved January 19, 2006.

The Effect of 24 Months Recombinant Human Growth Hormone (rh-GH) on LDL Cholesterol, Triglyceride-Rich Lipoproteins and apo [a] in Hypopituitary Adults Previously Treated with Conventional Replacement Therapy.pdf

This study concludes that the ultimate effect of GH therapy upon cardiovascular mortality remains to be determined and may be dose-related.
O'Neal, D.N., Hew, F.L., Best, J.D. & Alford, F. (1999). The effect of 24 months recombinant human growth hormone (rh-GH) on LDL cholesterol, triglyceride-rich lipoproteins and apo [a] in hypopituitary adults previously treated with conventional replacement therapy [Electronic version]. Growth Hormone & IGF Research: Official Journal of the Growth Hormone Research Society and the International IGF Research Society, 9(3), 165-173. Retrieved September 14, 2005.

Growth Hormone Treatment of Abdominally Obese Men Reduces Abdominal Fat Mass, Improves Glucose and Lipoprotein Metabolism, and Reduces Diastolic Blood Pressure.pdf

This trial has demonstrated that GH can favorably affect some of the multiple perturbations associated with abdominal/visceral obesity. This includes a reduction in abdominal/visceral obesity, an improved insulin sensitivity, and favorable effects on lipoprotein metabolism and diastolic blood pressure.
Johannsson, G., Marin, P., Lonn, L., Ottosson, M., Stenlof, K., Bjorntorp, P., et al. (1997). Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure [Electronic version]. The Journal of Clinical Endocrinology and Metabolism, 82(3), 727-734. Retrieved January 4, 2006.

Growth Hormone Substitution in Growth Hormone-Deficient Adults: Effects on Collagen Type I Synthesis and Skin Thickness.pdf

The purpose of this study was to prove whether stimulating collagen type I synthesis would be accompanied by a deposition of collagen type I in the skin.  It examined twenty growth hormone-deficient hypopituitary patients for twelve months.
Kann, P., Piepkorn, B., Schehler, B., Lotz, J., Prellwitz, W. & Beyer, J. (1996). Growth hormone substitution in growth hormone-deficient adults: effects on collagen type I synthesis and skin thickness [Electronic version]. Experimental and Clinical Endocrinology & Diabetes: Official Journal, German Society of Endocrinology [and] German Diabetes Association, 104(4), 327-333. Retrieved May 18, 2005.

Apolipoprotein-E Genotyping of Diabetic Dementia Patients: Is Diabetes Rare in Alzheimer's Disease?.pdf

This study concludes that diabetics with dementia rarely have AD except as a component of mixed dementia. Apo-E genotyping showed only average E4 allele frequency in diabetics compared with the high E4 frequency found in AD patients. However, mixed dementia in diabetics may be associated with the E4 allele, suggesting that close control of diabetes may be particularly important for those with E4 since they may be more likely than others to develop both diseases.
Nielson, K.A., Nolan, J.H., Berchtold, N.C., Sandman, C.A., Mulnard, R.A. & Cotman, C.W. (1996). Apolipoprotein-E genotyping of diabetic dementia patients: is diabetes rare in Alzheimer's disease? [Electronic version]. Journal of the American Geriatrics Society, 44(8), 897-904. Retrieved August 17, 2006.

The Effect of 3 Months of Recombinant Human Growth Hormone (GH) Therapy on Insulin and Glucose-Mediated Glucose Disposal and Insulin Secretion in GH-Deficient Adults: A Minimal Model Analysis.pdf

The authors of this study conclude that short term low dose rhGH treatment of GH-deficient adults induces a temporary state of mild glucose intolerance, hyperinsulinemia, insulin resistance, and raised NEFA levels at 1 week. By 3 months, these metabolic disturbances had returned to baseline for a persisting modest hyperinsulinemia. Whether this hyperinsulinemia will last over the longer term and/or has distant detrimental metabolic consequences in the individual must await further studies.  
O’Neal, D.N., Kalfas, A., Dunning, P.L., Christopher, M.J., Sawyer, S.D., Ward, G.M., et al. (1994). The effect of 3 months of recombinant human growth hormone (GH) therapy on insulin and glucose-mediated glucose disposal and insulin secretion in GH-deficient adults: a minimal model analysis [Electronic version]. The Journal of Clinical Endocrinology and Metabolism, 79(4), 975-983. Retrieved July 21, 2003.

Non-Responsiveness of Serum Gonadotropins and Testosterone to Pulsatile GnRH in Hemochromatosis Suggesting a Pituitary Defect.pdf

This study investigated the potential pituitary origin of gonadal insufficiency in hemochromatosis. Gonadotropin secretion was studied in seven patients with hemochromatosis and hypogonadism, before and after chronic pulsatile GnRH therapy.  It was concluded that hypogonadism in hemochromatosis is due to pituitary lesions.
Duranteau, L., Chanson, P., Blumberg-Tick, J., Thomas, G., Brailly, S., Lubetzki, J., et al. (1993). Non-responsiveness of serum gonadotropins and testosterone to pulsatile GnRH in hemochromatosis suggesting a pituitary defect [Electronic version]. Acta Endocrinologica (Copenh), 128(4), 351-354. Retrieved October 26, 2005.

Preclinical Hypogonadism in Genetic Hemochromatosis in the Early Stage of the Disease: Evidence of Hypothalamic Dysfunction.pdf

This study examined endocrine functions at baseline and after TRH and LHRH stimulation in a group of 7 young male patients with genetic hemochromatosis (HE) without liver damage (i.e. fibrosis and cirrhosis). In five patients endocrine re-evaluations after complete iron depletion was also performed.
Piperno, A., Rivolta, M.R., D'Alba, R., Fargion, S., Rovelli, F., Ghezzi, A., et al. (1992). Preclinical hypogonadism in genetic hemochromatosis in the early stage of the disease: evidence of hypothalamic dysfunction [Electronic version]. Journal of Endocrinological Investigation, 15(6), 423-428. Retrieved October 26, 2005.

Mechanism of Growth Hormone-Induced Postprandial Carbohydrate Intolerance in Humans.pdf

In this study, the decrease in postprandial glucose uptake did not appear to be mediated by a change in substrate uptake since postprandial plasma concentrations and forearm balance of lactate, free fatty acids, and ketone bodies did not differ in the presence and absence of growth hormone excess.
Butler, P., Kryshak, E. & Rizza, R. (1991). Mechanism of growth hormone-induced postprandial carbohydrate intolerance in humans [Electronic version]. The American Journal of Physiology, 261(6 Pt 1), preceeding E677. Retrieved July 23, 2003.

Increase in Renal Plasma Flow and Glomerular Filtration Rate During Growth Hormone Treatment May Be Mediated By Insulin-Like Growth Factor I.pdf

In this study, IGF-1 levels were examined in a man with hypothalamic growth hormone-deficiency before and during the first six days of treatment with daily growth hormone injections. 
Hirschberg, R.R. & Kopple, J.D. (1988). Increase in renal plasma flow and glomerular filtration rate during growth hormone treatment may be mediated by insulin-like growth factor I [Electronic version]. American Journal of Nephrology, 8(3), 249-254. Retrieved May 18, 2005.

Hypogonadotropic Hypogonadism in Hemochromatosis: Recovery of Reproductive Function After Iron Depletion.pdf

This study examined the effect of iron depletion on reproductive function in a 37-yr-old man with hypogonadotropic hypogonadism due to idiopathic hemochromatosis. It was concluded that phlebotomy alone may be adequate treatment for hypogonadotropic hypogonadism in men with hemochromatosis.
Siemons, L.J. & Mahler, C.H. (1987). Hypogonadotropic hypogonadism in hemochromatosis: recovery of reproductive function after iron depletion [Electronic version]. The Journal of Clinical Endocrinology and Metabolism, 65(3), 585-587. Retrieved October 26, 2005.